HomeAI · summaries
Storia in 2 fonti
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca licenses lung cancer drug Sunvozertinib from Dizal Pharmaceutical for $600 million upfront, plus potential milestones.
- ·
endpoints.news
AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront
AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.